Lupin (LUPIN) has received approval from the FDA for its Abbreviated New Drug Application for Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials. This is Lupin's first product using Nanomi B.V.'s technology and has a 180-day CGT exclusivity.
"Risperidone's U.S. FDA approval provides crucial validation of Nanomi's LAI technology platform and testifies to Lupin's ability to bring complex injectables to market," said Shahin Fesharaki, Chief Scientific Officer of Lupin.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.